{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:04:49Z","timestamp":1773291889083,"version":"3.50.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,24]]},"DOI":"10.1093\/infdis\/jiy175","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T19:14:40Z","timestamp":1522178080000},"page":"698-706","source":"Crossref","is-referenced-by-count":30,"title":["The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors"],"prefix":"10.1093","volume":"218","author":[{"given":"Hanh T","family":"Pham","sequence":"first","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Labrie","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg E A","family":"Wijting","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Hassounah","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka Yee","family":"Lok","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Portna","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E","family":"Goring","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingshan","family":"Han","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Lungu","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus University, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marchina E","family":"van der Ende","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bluma G","family":"Brenner","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Faculty of Surgery, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A","family":"Boucher","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus University, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart J A","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J A","family":"van Kampen","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus University, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Mespl\u00e8de","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montreal, Canada"},{"name":"Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Wainberg","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montreal, Canada"},{"name":"Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,3,29]]},"reference":[{"key":"key\n\t\t\t\t20180724083919_CIT0001","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0092-8674(91)90297-C","article-title":"HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer","volume":"67","author":"Engelman","year":"1991","journal-title":"Cell"},{"key":"key\n\t\t\t\t20180724083919_CIT0002","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"key\n\t\t\t\t20180724083919_CIT0003","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/jac\/dkw186","article-title":"Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia","volume":"71","author":"Katlama","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0004","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180724083919_CIT0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180724083919_CIT0006","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180724083919_CIT0007","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus Abacavir\/Lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180724083919_CIT0008","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.3390\/v7072790","article-title":"Resistance against integrase strand transfer inhibitors and relevance to HIV persistence","volume":"7","author":"Mespl\u00e8de","year":"2015","journal-title":"Viruses"},{"key":"key\n\t\t\t\t20180724083919_CIT0009","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180724083919_CIT0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180724083919_CIT0011","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180724083919_CIT0012","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0013","doi-asserted-by":"crossref","first-page":"e00157","DOI":"10.1128\/mBio.00157-17","article-title":"The R263K Dolutegravir resistance-associated substitution progressively decreases HIV-1 integration","volume":"8","author":"Mesplede","year":"2017","journal-title":"MBio"},{"key":"key\n\t\t\t\t20180724083919_CIT0014","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/jac\/dku199","article-title":"Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity","volume":"69","author":"Mespl\u00e8de","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-4690-10-22","article-title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","volume":"10","author":"Mespl\u00e8de","year":"2013","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180724083919_CIT0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-4690-11-7","article-title":"The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness","volume":"11","author":"Wares","year":"2014","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180724083919_CIT0017","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180724083919_CIT0018","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkv430","article-title":"Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients","volume":"71","author":"Gubavu","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0019","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/jac\/dkx109","article-title":"Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100000 copies\/mL: a medium-term follow-up","volume":"72","author":"Lanzafame","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0020","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/jac\/dkw154","article-title":"Dolutegravir monotherapy as a simplified strategy in virologically suppressed HIV-1-infected patients","volume":"71","author":"Moreira","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0021","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/jac\/dkw078","article-title":"Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression","volume":"71","author":"Rojas","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0022","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/QAI.0000000000000931","article-title":"Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies\/mL HIV RNA Load","volume":"72","author":"Lanzafame","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180724083919_CIT0023","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkw071","article-title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","volume":"71","author":"Brenner","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0024","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP3082","article-title":"Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results","volume":"22","author":"Oldenbuettel","year":"2017","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180724083919_CIT0025","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180724083919_CIT0026","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/infdis\/jiy176","article-title":"HIV-1 resistance dynamics in patients with no response to dolutegravir maintenance monotherapy","volume":"218","author":"Wijting","year":"2018","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180724083919_CIT0027","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1128\/AAC.00911-07","article-title":"Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137","volume":"52","author":"Hombrouck","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0028","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.00470-08","article-title":"Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors","volume":"82","author":"Goethals","year":"2008","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0029","doi-asserted-by":"crossref","first-page":"11459","DOI":"10.1128\/JVI.77.21.11459-11470.2003","article-title":"Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations","volume":"77","author":"Fikkert","year":"2003","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0030","unstructured":"Underwood M , DeAndaF, DoreyD, et al Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naive Subjects With Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762). 13th European HIV & Hepatitis Workshop. Barcelona, Spain, 2015."},{"key":"key\n\t\t\t\t20180724083919_CIT0031","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/jac\/dkx118","article-title":"HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton\/small clusters","volume":"72","author":"Brenner","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0032","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1128\/JVI.69.6.3712-3720.1995","article-title":"Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1","volume":"69","author":"Lusso","year":"1995","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0033","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J Gen Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0034","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1128\/JVI.00709-09","article-title":"Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1","volume":"83","author":"Platt","year":"2009","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0035","doi-asserted-by":"crossref","first-page":"12585","DOI":"10.1128\/JVI.01726-08","article-title":"Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research","volume":"82","author":"Takeuchi","year":"2008","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0036","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12977-016-0265-x","article-title":"Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI\/NNRTI resistant viruses","volume":"13","author":"Pham","year":"2016","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180724083919_CIT0038","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/JVI.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0039","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1128\/JVI.05584-11","article-title":"Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I\/V mutations","volume":"85","author":"Xu","year":"2011","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0040","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/AAC.00204-13","article-title":"Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir","volume":"57","author":"Huang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0041","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/TCRM.S2268","article-title":"Raltegravir: first in class HIV integrase inhibitor","volume":"4","author":"Temesgen","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"key\n\t\t\t\t20180724083919_CIT0042","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/jac\/dkx195","article-title":"Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice","volume":"72","author":"Heredia","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0043","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dkq326","article-title":"Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors","volume":"65","author":"Ceccherini-Silberstein","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083919_CIT0044","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1021\/bi972949c","article-title":"Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex","volume":"37","author":"Heuer","year":"1998","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20180724083919_CIT0045","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1093\/emboj\/20.13.3565","article-title":"Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes","volume":"20","author":"Gao","year":"2001","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t20180724083919_CIT0046","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jmb.2008.10.083","article-title":"Defining the DNA substrate binding sites on HIV-1 integrase","volume":"385","author":"Dolan","year":"2009","journal-title":"J Mol Biol"},{"key":"key\n\t\t\t\t20180724083919_CIT0047","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1073\/pnas.150220297","article-title":"Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding","volume":"97","author":"Chen","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180724083919_CIT0048","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.aah5163","article-title":"Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome","volume":"355","author":"Passos","year":"2017","journal-title":"Science"},{"key":"key\n\t\t\t\t20180724083919_CIT0049","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1128\/JVI.03485-14","article-title":"Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions","volume":"89","author":"Anstett","year":"2015","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083919_CIT0050","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1093\/molbev\/msx251","article-title":"Evidence for the Selective Basis of Transition-to-Transversion Substitution Bias in Two RNA Viruses","volume":"34","author":"Lyons","year":"2017","journal-title":"Mol Biol Evol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/218\/5\/698\/25206878\/jiy175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T08:00:53Z","timestamp":1604044853000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/218\/5\/698\/4956223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,3,29]]},"published-print":{"date-parts":[[2018,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy175","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9,1]]},"published":{"date-parts":[[2018,3,29]]}}}